Aligos Therapeutics Announces $105 Million Private Placement Financing
Portfolio Pulse from
Aligos Therapeutics has secured $105 million through a private placement to fund its Phase 2 clinical study of ALG-000184 and extend its cash runway into the second half of 2026.
February 12, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aligos Therapeutics has announced a $105 million private placement to fund its Phase 2 clinical study of ALG-000184, extending its cash runway into the second half of 2026.
The $105 million private placement provides significant funding for Aligos Therapeutics, supporting its Phase 2 clinical study and extending its financial stability. This positive financial development is likely to boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100